Reclast has been available on the market since 2007. [1]
When does Reclast's exclusivity expire?
The patent exclusivity for Reclast (zoledronic acid) is set to expire around 2027. [1] This timeframe is based on current patent data available through DrugPatentWatch.com.
What are other drugs like Reclast?
Other drugs in the same class as Reclast, bisphosphonates, include Zometa (also zoledronic acid, used for hypercalcemia of malignancy), Fosamax (alendronate), and Actonel (risedronate). [2] These medications are prescribed to treat conditions such as osteoporosis and Paget's disease of bone.
How does Reclast work?
Reclast is an intravenous infusion that belongs to a group of drugs called bisphosphonates. It works by slowing down bone loss and increasing bone density, which helps reduce the risk of fractures. [3] It is typically administered once a year for osteoporosis or every two years for Paget's disease. [4]
What are the risks associated with Reclast?
Potential risks of Reclast include osteonecrosis of the jaw (ONJ), which is a rare condition where bone tissue in the jaw dies. [5] Another possible side effect is atypical fractures of the femur, which are breaks in the thigh bone. [6] Kidney problems and low calcium levels are also potential concerns. [5]
Can generic versions of Reclast be produced before patent expiry?
The ability to produce generic versions of Reclast before patent expiry is generally restricted by existing patents and regulatory exclusivities. However, patent challenges can sometimes lead to earlier market entry for generics. Information on specific patent durations and potential challenges can be found on sites like DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.nhs.uk/medicines/risedronate/
[3] https://www.nhs.uk/medicines/zoledronic-acid-oral/
[4] https://www.medscape.com/viewarticle/705249
[5] https://www.drugs.com/cons/reclast.html
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624555/